You are here

High Response Rates Reported With Hepatitis C Vaccines in Phase II Trial

Study evaluates triple therapy plus ribavirin (Apr. 23)

Three investigational direct-acting antivirals (DAAs) — ABT-267, ABT-333, and ABT-450/r (AbbVie) — have shown high sustained viral response (SVR) rates against genotype 1 (GT1) hepatitis C virus (HCV) infection in a phase IIb trial. SVRs of greater than 90% were achieved in treatment-naïve patients and in patients who had previously failed treatment with pegylated interferon (peg-IFN) and ribavirin (null responders).

The study’s objective was to assess the safety and efficacy of the combination of ABT-450/r (dosed 100/100 to 200/100 mg once daily), ABT-267 (25 mg once daily), and ABT-333 (400 mg twice daily) plus ribavirin in non-cirrhotic, treatment-naïve patients and in prior peg-IFN/ribavirin null responders after 8, 12, and 24 weeks of treatment. Enrollment was open to GT1-infected patients regardless of interleukin (IL)-28B host genotype.

Among the treatment-naïve patients, 99% achieved SVR at 12 weeks (SVR12), and 96% achieved SVR at 24 weeks (SVR24). Among the null responders, 93% achieved both SVR12 and SVR24.

Comparable SVR24 rates were also seen in treatment-naïve patients and in null responders across HCV subtypes, IL-28B host genotypes, baseline HCV-RNA levels, and severity of fibrosis.

Of the 247 patients included in this analysis, four (1.6%) discontinued treatment because of drug-related adverse events (AEs). Serious AEs occurred in four patients (1.6%), with one event (arthralgia) considered possibly drug-related. Other AEs (reported in more than 10% of patients) included headache, fatigue, nausea, insomnia, and diarrhea. Six patients experienced grade-3 or -4 laboratory abnormalities in total bilirubin, and one patient experienced alanine aminotransferase (ALT) abnormalities; all events resolved with continued dosing.

The triple-DAA combination is currently being studied in phase III clinical trials.

There is currently no vaccine for HCV infection.

Source: Abbvie; April 23, 2013.

More Headlines

Liver Fluke Infestation Affects Almost 2.5 Million People Globally
Policy Could Be Life-Changing for People With Spinal Cord Injury
Test Determines Severity of Pain, Helps Physicians Select Best Options
Intratumoral Injection Stimulates Immune Activation
Diabetes and Cancer Patients Could Soon Avoid Injections
Early Cancer Development May Begin in Just 30 Minutes